Machine learning and memory loss
ML provides powerful tools for analysing complex neurological data. Recent studies outline a range of ML techniques, such as neural networks and decision trees, which have been shown to work with brain-related datasets (note 4). These methods can detect patterns in large volumes of data, often revealing correlations that traditional approaches might overlook. Other studies highlight the role of deep learning in medical imaging (note 5). In particular, convolutional neural networks have been applied to MRI and CT scans with promising results, detecting early signs of neurological disorders such as Alzheimer’s disease. By digitizing the analysis of brain scans, ML can improve diagnostic accuracy while also reducing the time and bias linked to manual evaluations. Taken together, this research demonstrates how ML’s adaptability and precision make it a useful tool in neuroscience, helping to turn data into meaningful clinical insights. ML can change how memory loss is treated through early detection and emerging therapies such as BCIs. Studies show that ML models can analyse brain scans to detect early signs of Alzheimer’s disease with greater accuracy than traditional methods (note 3). This matters because earlier diagnosis makes earlier intervention possible, which can slow disease progression. Other research also notes that AI can assist doctors by highlighting minor abnormalities on scans that might be missed (note 2). These findings suggest that ML could become a valuable support tool in clinical practice, helping to reduce errors and improve patient care. Beyond diagnosis, ML is also being explored in treatment. Lancet Neurology examined BCIs designed to restore memory in patients with damage to brain regions. 6 Early results are encouraging, with some patients showing improvement after intervention. Even so, BCIs present challenges. Surgical implantation carries risks, and questions remain about whether benefits justify those risks. Cost is another concern, as advanced treatments may only be available to wealthier patients unless steps are taken to improve access. One challenge in clinical practice is the interpretability of ML models. While they excel at finding complex patterns in medical data, as demonstrated by Esteva et al. in their work on deep learning for medical imaging, they often function as ‘black boxes’ - one cannot easily understand how the model reached its conclusion (note 5). For instance, an ML system analysing neuroimaging data might label a brain scan as ‘high risk’ for Alzheimer's without explaining which features led to this assessment (note 3). 3 Obermeyer’s article shows how this lack of interpretability creates barriers to clinical adoption, as doctors hesitate to trust technology they cannot understand. 7 To address
6 See The Lancet Neurology. ‘Brain-Computer Interfaces for Cognitive Rehabilitation.’ The Lancet
Neurology 20, no. 5 (2021). Accessed 7th July 2025. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00059-4/fulltext. 7 See Obermeyer, Z. and E. Emanuel. 2016. ‘Predicting the Future---Big Data, Machine Learning, and Clinical
Medicine.’ New England Journal of Medicine 375, no. 13 (2016). Accessed 7th July 2025.
https://www.nejm.org/doi/full/10.1056/NEJMp1606181.
108
Made with FlippingBook - PDF hosting